Jane Street Group, LLC Exact Sciences Corp Transaction History

Jane Street Group, LLC

$88.2 Billion
Q2 2024

A detailed history of Jane Street Group, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Jane Street Group, LLC holds 429,673 shares of EXAS stock, worth $30.3 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

429,673

Previous 344,735 24.64%

Holding current value

$30.3 Million

Previous $23.8 Million 23.75%

% of portfolio

0.02%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$41.33 - $74.26 $3.51 Million - $6.31 Million	84,938 Added 24.64%	429,673 $18.2 Million
Q1 2024 May 15, 2024	BUY	$56.27 - $73.77 $7.78 Million - $10.2 Million	138,262 Added 66.96%	344,735 $23.8 Million
Q4 2023 Feb 14, 2024	BUY	$59.06 - $75.72 $6.82 Million - $8.74 Million	115,452 Added 126.84%	206,473 $15.3 Million
Q3 2023 Nov 14, 2023	SELL	$65.94 - $99.04 $3.21 Million - $4.82 Million	-48,677 Reduced 34.84%	91,021 $6.21 Million
Q2 2023 Aug 14, 2023	SELL	$62.68 - $95.05 $1.08 Million - $1.63 Million	-17,155 Reduced 10.94%	139,698 $13.1 Million
Q1 2023 May 15, 2023	SELL	$47.19 - $70.77 $2.65 Million - $3.98 Million	-56,252 Reduced 26.4%	156,853 $10.6 Million
Q4 2022 Feb 14, 2023	BUY	$30.35 - $53.15 $3.99 Million - $6.99 Million	131,462 Added 161.02%	213,105 $10.6 Million
Q3 2022 Nov 14, 2022	BUY	$31.97 - $49.37 $42,104 - $65,020	1,317 Added 1.64%	81,643 $2.65 Million
Q2 2022 Aug 16, 2022	SELL	$35.61 - $76.23 $1.45 Million - $3.11 Million	-40,732 Reduced 33.65%	80,326 $3.16 Million
Q1 2022 May 17, 2022	SELL	$57.56 - $82.54 $6.37 Million - $9.14 Million	-110,674 Reduced 47.76%	121,058 $8.47 Million
Q4 2021 Feb 15, 2022	BUY	$72.5 - $100.68 $10.1 Million - $14 Million	138,943 Added 149.74%	231,732 $18 Million
Q3 2021 Nov 16, 2021	BUY	$90.24 - $124.05 $2.24 Million - $3.08 Million	24,863 Added 36.6%	92,789 $8.86 Million
Q2 2021 Aug 16, 2021	SELL	$93.66 - $139.27 $1.41 Million - $2.1 Million	-15,071 Reduced 18.16%	67,926 $8.44 Million
Q1 2021 May 18, 2021	SELL	$116.57 - $155.01 $3.11 Million - $4.14 Million	-26,719 Reduced 24.35%	82,997 $10.9 Million
Q4 2020 Feb 17, 2021	BUY	$99.61 - $142.12 $7.03 Million - $10 Million	70,588 Added 180.4%	109,716 $14.5 Million
Q3 2020 Nov 17, 2020	BUY	$72.92 - $102.01 $1.26 Million - $1.76 Million	17,216 Added 78.57%	39,128 $3.99 Million
Q2 2020 Aug 17, 2020	BUY	$55.75 - $92.75 $832,236 - $1.38 Million	14,928 Added 213.75%	21,912 $1.91 Million
Q1 2020 May 15, 2020	SELL	$37.9 - $104.44 $6.69 Million - $18.4 Million	-176,399 Reduced 96.19%	6,984 $405,000
Q4 2019 Feb 14, 2020	BUY	$77.66 - $99.74 $7.84 Million - $10.1 Million	101,017 Added 122.64%	183,383 $17 Million
Q3 2019 Nov 14, 2019	BUY	$90.37 - $122.49 $5.88 Million - $7.97 Million	65,074 Added 376.32%	82,366 $7.44 Million
Q2 2019 Aug 15, 2019	SELL	$89.51 - $118.04 $7.6 Million - $10 Million	-84,952 Reduced 83.09%	17,292 $2.04 Million
Q1 2019 May 16, 2019	BUY	$61.98 - $96.5 $5.35 Million - $8.33 Million	86,304 Added 541.43%	102,244 $8.86 Million
Q4 2018 Feb 15, 2019	SELL	$56.04 - $82.66 $540,505 - $797,255	-9,645 Reduced 37.7%	15,940 $1.01 Million
Q3 2018 Nov 14, 2018	SELL	$48.29 - $80.6 $13.9 Million - $23.1 Million	-286,973 Reduced 91.81%	25,585 $2.02 Million
Q2 2018 Aug 15, 2018	BUY	$37.84 - $69.96 $11.6 Million - $21.4 Million	306,101 Added 4740.61%	312,558 $18.7 Million
Q1 2018 May 15, 2018	SELL	$39.82 - $57.53 $530,482 - $766,414	-13,322 Reduced 67.35%	6,457 $260,000
Q4 2017 Feb 15, 2018	BUY	$46.49 - $60.51 $580,846 - $756,011	12,494 Added 171.5%	19,779 $1.04 Million
Q3 2017 Nov 14, 2017	BUY	$37.05 - $47.12 $269,909 - $343,269	7,285	7,285 $343,000

Others Institutions Holding EXAS

# of Institutions

637

Shares Held

166M

Call Options Held

1.93M

Put Options Held

1.23M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $12.5B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Exact Sciences Corp Transaction History